BioMed Research International

Research Article

Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy

Table 3

Association of ABCG2 gene polymorphisms with therapeutic response to preoperative neoadjuvant anthracycline-based chemotherapy ().


Variable	Number	RECIST		^†	Adjusted OR (95% CI)^‡
Variable	Number	CR and PR (%)	SD and PD (%)	^†	Adjusted OR (95% CI)^‡

ABCG2 G34A
GG	69	40 (58.0)	29 (42.0)		1 (reference)
GA	60	33 (55.0)	27 (45.0)	0.844	0.931 (0.456–1.902)
AA	19	9 (47.4)	10 (52.6)	0.205	0.490 (0.163–1.474)
GA/AA	79	42 (53.2)	37 (46.8)	0.540	1.233 (0.632–2.405)
ABCG2 C421A
CC	70	39 (55.7)	31 (44.3)		1 (reference)
CA	67	35 (52.2)	32 (47.8)	0.771	0.902 (0.449–1.810)
AA	11	8 (72.7)	3 (27.3)	0.041	4.669 (0.826–26.388)
CA/AA	78	43 (55.1)	35 (44.9)	0.798	1.091 (0.559–2.133)

RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; PD, progressive disease; SD, stable disease.
^† values were calculated from chi-square tests or Fisher’s exact test.
^‡Adjusted OR and 95% CI values were calculated by unconditional logistic regression adjusted for age and menopause status.